Rep. Josh Gottheimer Buys Johnson & Johnson (NYSE:JNJ) Stock

Representative Josh Gottheimer (D-New Jersey) recently bought shares of Johnson & Johnson (NYSE:JNJ). In a filing disclosed on February 10th, the Representative disclosed that they had bought between $1,001 and $15,000 in Johnson & Johnson stock on January 21st. The trade occurred in the Representative’s “MORGAN STANLEY – SELECT UMA ACCOUNT # 1” account.

Representative Josh Gottheimer also recently made the following trade(s):

• Sold $1,001 – $15,000 in shares of Microsoft (NASDAQ:MSFT) on 1/31/2025.
• Sold $1,001 – $15,000 in shares of Arista Networks (NYSE:ANET) on 1/31/2025.
• Purchased $1,001 – $15,000 in shares of Visa (NYSE:V) on 1/31/2025.
• Purchased $1,001 – $15,000 in shares of Tesla (NASDAQ:TSLA) on 1/31/2025.
• Purchased $1,001 – $15,000 in shares of Alibaba Group (NYSE:BABA) on 1/31/2025.
• Purchased $1,001 – $15,000 in shares of Twilio (NYSE:TWLO) on 1/31/2025.
• Sold $1,001 – $15,000 in shares of ICF International (NASDAQ:ICFI) on 1/31/2025.
• Purchased $1,001 – $15,000 in shares of Mastercard (NYSE:MA) on 1/31/2025.
• Purchased $1,001 – $15,000 in shares of Visa (NYSE:V) on 1/30/2025.
• Purchased $1,001 – $15,000 in shares of 3M (NYSE:MMM) on 1/30/2025.

Johnson & Johnson Stock Down 0.7 %

JNJ stock traded down $1.09 during trading on Wednesday, hitting $155.04. 2,179,008 shares of the company’s stock traded hands, compared to its average volume of 8,864,698. The business has a fifty day simple moving average of $147.48 and a two-hundred day simple moving average of $156.01. The company has a quick ratio of 0.79, a current ratio of 1.03 and a debt-to-equity ratio of 0.45. The firm has a market capitalization of $373.27 billion, a P/E ratio of 23.32, a PEG ratio of 2.46 and a beta of 0.52. Johnson & Johnson has a 1 year low of $140.68 and a 1 year high of $168.85.

Johnson & Johnson (NYSE:JNJ) last posted its earnings results on Wednesday, January 22nd. The company reported $2.04 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.99 by $0.05. Johnson & Johnson had a return on equity of 34.35% and a net margin of 18.20%. The company had revenue of $22.52 billion for the quarter, compared to analyst estimates of $22.44 billion. During the same quarter in the previous year, the firm earned $2.29 earnings per share. The firm’s quarterly revenue was up 5.3% compared to the same quarter last year. Sell-side analysts anticipate that Johnson & Johnson will post 10.58 EPS for the current year.

Johnson & Johnson Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, March 4th. Stockholders of record on Tuesday, February 18th will be given a $1.24 dividend. The ex-dividend date of this dividend is Tuesday, February 18th. This represents a $4.96 annualized dividend and a dividend yield of 3.20%. Johnson & Johnson’s payout ratio is presently 74.59%.

Hedge Funds Weigh In On Johnson & Johnson

Large investors have recently bought and sold shares of the business. Transamerica Financial Advisors Inc. lifted its position in shares of Johnson & Johnson by 7.1% during the 4th quarter. Transamerica Financial Advisors Inc. now owns 11,204 shares of the company’s stock worth $1,621,000 after buying an additional 746 shares during the last quarter. WealthTrak Capital Management LLC purchased a new stake in Johnson & Johnson in the fourth quarter valued at $26,000. Intrust Bank NA boosted its stake in Johnson & Johnson by 1.9% in the fourth quarter. Intrust Bank NA now owns 20,242 shares of the company’s stock valued at $2,927,000 after acquiring an additional 370 shares in the last quarter. Hobbs Group Advisors LLC grew its holdings in shares of Johnson & Johnson by 25.9% during the fourth quarter. Hobbs Group Advisors LLC now owns 1,481 shares of the company’s stock worth $214,000 after purchasing an additional 305 shares during the last quarter. Finally, Biondo Investment Advisors LLC increased its position in shares of Johnson & Johnson by 2.2% during the fourth quarter. Biondo Investment Advisors LLC now owns 58,674 shares of the company’s stock worth $8,485,000 after purchasing an additional 1,289 shares in the last quarter. Hedge funds and other institutional investors own 69.55% of the company’s stock.

Analysts Set New Price Targets

JNJ has been the subject of a number of recent analyst reports. Wolfe Research assumed coverage on Johnson & Johnson in a research report on Friday, November 15th. They issued an “outperform” rating and a $190.00 price objective for the company. Morgan Stanley reduced their price objective on shares of Johnson & Johnson from $175.00 to $163.00 and set an “equal weight” rating for the company in a research report on Thursday, January 23rd. Royal Bank of Canada reiterated an “outperform” rating and issued a $181.00 target price on shares of Johnson & Johnson in a research report on Thursday, January 23rd. Bank of America cut their price objective on shares of Johnson & Johnson from $160.00 to $159.00 and set a “neutral” rating for the company in a report on Thursday, January 23rd. Finally, Guggenheim upped their price target on Johnson & Johnson from $162.00 to $166.00 and gave the company a “neutral” rating in a research report on Monday, February 3rd. Nine investment analysts have rated the stock with a hold rating, eight have assigned a buy rating and two have given a strong buy rating to the company’s stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $170.67.

Insider Activity

In other Johnson & Johnson news, Director Mark A. Weinberger bought 1,000 shares of Johnson & Johnson stock in a transaction dated Thursday, December 12th. The stock was acquired at an average cost of $147.22 per share, with a total value of $147,220.00. Following the completion of the acquisition, the director now owns 1,000 shares of the company’s stock, valued at approximately $147,220. This represents a ? increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Company insiders own 0.16% of the company’s stock.

About Representative Gottheimer

Josh Gottheimer (Democratic Party) is a member of the U.S. House, representing New Jersey’s 5th Congressional District. He assumed office on January 3, 2017. His current term ends on January 3, 2027.

Gottheimer (Democratic Party) is running for re-election to the U.S. House to represent New Jersey’s 5th Congressional District. He declared candidacy for the 2026 election.

Gottheimer is also running for election for Governor of New Jersey. He declared candidacy for the Democratic primary scheduled on June 10, 2025.

Gottheimer attended the University of Pennsylvania for his undergraduate degree. He became a Thouron Fellow at Oxford and attended Harvard Law School. Gottheimer worked as a speech writer under former President Bill Clinton (D), assisting with two State of the Union addresses, among other projects. Before running for Congress, he worked for Microsoft as a general manager for corporate strategy.

About Johnson & Johnson

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.